The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Congenital Hyperinsulinism: Diagnosis and Treatment Update
Open accessAbstract
Pancreatic β-cells are finely tuned to secrete insulin so that plasma glucose levels are maintained within a narrow physiological range (3.5-5.5 mmol/L). Hyperinsulinaemic hypoglycaemia (HH) is the inappropriate secretion of insulin in the presence of low plasma glucose levels and leads to severe and persistent hypoglycaemia in neonates and children. Mutations in 12 different key genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, HK1, PGM1 and PMM2) that are involved in the regulation of insulin secretion from pancreatic β-cells have been described to be responsible for the underlying molecular mechanisms leading to congenital HH. In HH due to the inhibitory effect of insulin on lipolysis and ketogenesis there is suppressed ketone body formation in the presence of hypoglycaemia thus leading to increased risk of hypoglycaemic brain injury. Therefore, a prompt diagnosis and immediate management of HH is essential to avoid hypoglycaemic brain injury and long-term neurological complications in children. Advances in molecular genetics, imaging techniques (18F-DOPA positron emission tomography/computed tomography scanning), medical therapy and surgical advances (laparoscopic and open pancreatectomy) have changed the management and improved the outcome of patients with HH. This review article provides an overview to the background, clinical presentation, diagnosis, molecular genetics and therapy in children with different forms of HH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Ketone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966
Thomas, P. M., Cote, G. J., Wohllk, N., Haddad, B., Mathew, P. M., Rabl, W., Aguilar-Bryan, L., Gagel, R. F., & Bryan, J. (1995) · Science · doi:10.1126/science.7716548 · Cited by 806
Goldfine, A. B., Mun, E. C., Devine, E., Bernier, R., Baz-Hecht, M., Jones, D. B., Schneider, B. E., Holst, J. J., & Patti, M. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0918 · Cited by 377
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“Exendin-(9-39) is a specific GLP-1 receptor antagonist in mice and humans (161,162).”
BackgroundChan, C. B., De Leo, D., Joseph, J. W., McQuaid, T. S., Ha, X. F., Xu, F., Tsushima, R. G., Pennefather, P. S., Salapatek, A. M. F., & Wheeler, M. B. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1302 · Cited by 341
Renström, E., Eliasson, L., & Rorsman, P. (1997) · The Journal of Physiology · doi:10.1111/j.1469-7793.1997.105bl.x · Cited by 299
Sulphonylurea action revisited: the post-cloning era
Gribble, F. M., & Reimann, F. (2003) · Diabetologia · doi:10.1007/s00125-003-1143-3 · Cited by 284
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism
Kapoor, R. R., Flanagan, S. E., Arya, V. B., Shield, J. P., Ellard, S., & Hussain, K. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0673 · Cited by 243 · cited 4×
“HH can be transient due to certain risk factors, such as birth asphyxia, intra-uterine growth retardation, maternal diabetes mellitus (5), or associated with various overgrowth syndromes like Beckwith-Wiedemann syndrome or metabolic conditions such as congenital disorders of glycosylation (6).”
BackgroundInfluentialSelf-citation
Cited by
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies
Salehi, M., Vella, A., McLaughlin, T., & Patti, M.-E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00528 · Cited by 239
Metadata
- Authors
- Demirbilek, H., & Hussain, K.
- Venue
- Journal of Clinical Research in Pediatric Endocrinology
- Publisher
- Galenos Yayinevi
- Published
- 2018-01-15
- Volume
- 9
- Issue
- Suppl 2
- Pages
- 69-87
- ISSN
- 1308-5727 (ISSN-L)
- OpenAlex
- W2783695354
- Cited by
- 163
- References
- 13
- FWCI
- 17.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Congenital Hyperinsulinism: Diagnosis and Treatment Update. https://app.cochat.ai/papers/10.4274/jcrpe.2017.s007
- The paper
- Demirbilek, H., & Hussain, K. (2018). Congenital Hyperinsulinism: Diagnosis and Treatment Update. Journal of Clinical Research in Pediatric Endocrinology. https://doi.org/10.4274/jcrpe.2017.s007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.